Effect of dialyzer geometry on granulocyte and complement activation.
During hemodialysis with cuprophan membranes, the complement system as well as leukocytes become activated. In order to clarify the role of dialyzer geometry, the effect of hollow-fiber versus flat-sheet dialyzers and of different surface areas on C3a generation and leukocyte degranulation was investigated. Plasma levels of leukocyte elastase in complex with alpha 1-proteinase inhibitor were significantly increased after 1 h (+55%) and 3 h (+62%) of hemodialysis with flat-sheet dialyzers as compared to hollow-fiber devices. In addition, plasma levels of lactoferrin, released from the specific granules of leukocytes during activation, were significantly higher (+42%) 3 h after the onset of dialysis treatment with flat-sheet than with hollow-fiber dialyzers. With respect to surface area, larger dialyzers tended to cause more release of leukocyte elastase as compared to dialyzers with smaller surface areas, irrespectively of the configuration of the dialyzer used. On the other hand, activation of the complement system, as measured by the generation of C3a-desarg, did not differ with both types of configurations. The same held true for leukopenia, which was almost identical for hollow-fiber and flat-sheet dialyzers. From these findings two lines of evidence emerge: First, not only the type of membrane material used in a dialyzer may influence its biocompatibility, but the geometry of the extracorporeal device also determines the degree of compatibility. Hence, the extent of leukocyte activation correlated with both configuration of the dialyzer and surface area of the membrane.(ABSTRACT TRUNCATED AT 250 WORDS)
D000328:Adult; D000368:Aged; D001672:Biocompatible Materials; D001798:Blood Proteins; D002482:Cellulose / Q000009:adverse effects / Q000031:analogs & derivatives; D003167:Complement Activation; D003176:Complement C3 / Q000031:analogs & derivatives / Q000096:biosynthesis; D015926:Complement C3a; D006098:Granulocytes / Q000201:enzymology / Q000502:physiology*; D006801:Humans; D007688:Kidneys, Artificial / Q000009:adverse effects; D007970:Leukopenia / Q000209:etiology; D008875:Middle Aged; D010196:Pancreatic Elastase / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects; D000515:alpha 1-Antitrypsin
D001672:Biocompatible Materials; D001798:Blood Proteins; D003176:Complement C3; D000515:alpha 1-Antitrypsin; C044541:complement C3a, des-Arg-(77)-; D015926:Complement C3a; D002482:Cellulose; C009865:cuprammonium cellulose; D010196:Pancreatic Elastase